中文After nearly three decades, the foundational document governing how pharmaceutical packaging is evaluated in the United States has been replaced. In August 2026 the US Food and Drug Administration released draft guidance titled Container Closure Systems for Human Drugs and Biological Products, retiring both the agency’s 1999 guidance on container closure systems and the 2002 questions-and-answers companion that had been quietly doing much of the interpretive heavy lifting ever since.
The gap between 1999 and 2026 is not merely chronological. It spans the arrival of biologics as a dominant modality, the proliferation of prefilled delivery devices, the industrialisation of cold-chain logistics, and the maturation of quality risk management as a formal discipline rather than an informal instinct. The new draft reflects all of it, and the single most important change is conceptual: FDA now expects sponsors to evaluate the container closure system as an integrated whole, together with the risks it presents across the entire product lifecycle, rather than assessing packaging components one at a time in isolation.
That reframing has teeth. Under the older model, a sponsor could demonstrate that a vial met specification, that a stopper met specification, and that a seal met specification, and assemble those findings into a suitability argument. The new draft asks a harder question: does this system, as assembled, handled, shipped, stored and used, protect the product and the patient? Component-level data still matters, but it is now evidence in service of a system-level conclusion rather than the conclusion itself.
Quality risk management is the explicit foundation. The 1999 guidance did acknowledge that risk varies by dosage form and route of administration — an injectable is not a tablet — but the 2026 draft goes considerably further, establishing risk assessment as the organising principle of the whole evaluation. This aligns container closure work with the science- and risk-based approach that already governs chemistry, manufacturing and controls more broadly, and it means the depth of testing a sponsor must justify now scales with the criticality of the product rather than following a uniform checklist.
Container closure integrity testing receives a marked promotion. Leak testing and container integrity were addressed in 1999, but the new draft positions integrity testing as a critical element in demonstrating that a system remains suitable for its intended use throughout the product’s shelf life, with particular emphasis on sterile products. For sterile manufacturers, the practical implication is that integrity data is expected to be lifecycle data, not a one-time release result.
Extractables and leachables see perhaps the sharpest escalation in expectation. The 1999 document treated them as one component of a broader suitability assessment and offered general testing recommendations. The 2026 draft calls for substantially more thorough testing, formal safety and toxicological evaluation, and ongoing monitoring. The guidance states plainly that extractables and leachables assessment is an integral part of a system’s suitability evaluation, that these studies and associated toxicological assessments should be performed for any drug likely to interact with its packaging components in a way that introduces leached substances into the patient, and that a risk-based approach should govern both the original study design and any subsequent changes to packaging components.
That last clause deserves attention from anyone managing a marketed product. Packaging changes — a resin regrade, a new stopper supplier, a coating modification — are routine commercial events, and the guidance makes clear that risk-based extractables and leachables thinking applies to them, not just to original filings.
Manufacturing process effects are also expanded. FDA now expects sponsors to evaluate how washing, coating, sterilisation and depyrogenation may affect the suitability, compatibility and functionality of the container closure system. These are processes the packaging supplier typically performs, which pushes the evaluation upstream into the supply chain and raises the bar on supplier qualification and technical data sharing.
Distribution gets similar treatment, and this is where the draft most clearly reflects the last twenty years of reality. The guidance places substantially greater emphasis on shipping, handling, storage and cold-chain conditions, recognising that packaging performance must hold throughout distribution and not merely at the point of manufacture. FDA notes directly that a system’s seal integrity can be transiently compromised at extreme storage conditions or during shipping and handling, in ways that could affect product quality and safety. A transient breach that reseals is invisible to a release test and potentially significant to a patient — which is precisely why lifecycle integrity thinking now matters.
Combination products are addressed far more explicitly than before, with prefilled syringes, infusion pumps, metered-dose inhalers and IV bags named specifically. Where the container closure system also functions as the delivery device, FDA expects testing that demonstrates device function and delivery performance, with verification and validation of drug delivery performance after shipping, during storage, and in use. That is a device-grade evidentiary standard applied to something a packaging engineer may still think of as a container.
For packaging professionals, the takeaway is that the discipline has been formally repositioned. Container closure work is no longer a qualification exercise completed before launch and revisited only when something breaks. It is a lifecycle risk-management responsibility spanning suppliers, manufacturing, logistics and clinical use — and the documentation burden now matches that scope. Sponsors with legacy products qualified under the 1999 framework should expect gaps, particularly on extractables monitoring and distribution-condition integrity.
Source: Based on reporting from Packaging Digest.
